GNF2133
GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 μM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes[1].
Product Specifications
CAS Number
2561414-56-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
DYRK
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/gnf2133.html
Purity
99.67
Solubility
DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CCN1CCN(CC1)C(NC2=NC=CC(C3=CN(C4=CN=CC=C34)C5CCOCC5)=C2)=O
Molecular Formula
C24H30N6O2
Molecular Weight
434.53
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
DYRK1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CDX2 / Caudal Type Homeobox 2 (GI Epithelial Marker) (CDX2/2214), CF594 conjugate, 0.1mg/mL
FITC Conjugated Goat Affinity Purified Antibody to Human Immunoglobulins,
